- $430.67m
- $372.45m
Forte Biosciences slips for fifth session; CEO, CFO trims stake
U.S. STOCKS ON THE MOVE-Forte Biosciences, Sphere 3D, Tilly's, vaccine stocks, gold miners
U.S. STOCKS ON THE MOVE-Forte Biosciences, Sphere 3D, Future Fintech, gold miners
U.S. STOCKS ON THE MOVE-Didi, Forte Biosciences, Future Fintech, MongoDB
Forte Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview
Forte Biosciences plunges after scrapping plans to develop main drug candidate
U.S. RESEARCH ROUNDUP-Forte Biosciences, Mongodb, Veeva Systems
NASDAQ RESUMED AT 04:35 PM
NASDAQ TRADE HALT HALT NEWS DISSEMINATION AT 04:11 PM
U.S. STOCKS ON THE MOVE-Tesla, Home Depot, Powerbridge Technologies, Gaotu Techedu
Forte Biosciences rises after saying skin disease trial data will be released in Sept
Brief: Forte Biosciences, Inc. To Review The Second Quarter 2021 Results And Expects To Announce Topline Data From Phase 2 Clinical Trial Of FB-401 For The Treatment Of Atopic Dermatitis On Sept. 7
Forte Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Forte Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview
Forte Biosciences Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Forte Biosciences Inc Files For Mixed Shelf Of Up To $300 Million
Brief: Forte Biosciences Says Point72 Asset Management Lp Reports 5.2% Passive Stake In Co
Forte Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Forte Biosciences Reports Qtrly Net Loss Per Share $0.36